Key points from article :
Johnson & Johnson is paying $30 million upfront in cash for the global rights of a phase 3 cancer prospect at Nanobiotix.
The candidate, NBTXR3, enhances the efficacy of radiotherapy to improve outcomes in tumor types.
Metabolically inert nano- particles in NBTXR3 interact with X-rays, driving more electrons to increase the death of cancer cells.
Plans to run a phase 3 trial in recurrent and metastatic head and neck cancer in combination with an anti-PD-1 drug.
The Big Pharma may provide “in-kind regulatory and development support” worth a further $30 million “at its sole discretion.”
Deal also features a $5 million investment in Nanobiotix, with a second $25 million tranche potentially following in a future financing.
Bigger paydays await Nanobiotix if the phase 3 trial hits its endpoints and triggers a successful development and commercialization.
The deal is worth up to $1.8 billion in development, regulatory and sales milestones.
